ziresovir
ArkBio Wins China IND Clearance for Flu Antiviral AK0406
Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announced on August 12 that China’s National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for AK0406, an injectable candidate the company describes as, in its words, the first influenza antiviral drug-Fc conjugate to enter clinical development in China. ArkBio is privately held and does…
